Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon`s, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as...
Website: angiodynamics.com



Growth: Pretty weak revenue growth rate 9.5%, there is slowdown compared to average historical growth rates 25.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1.8%. On average the margin is decreasing steadily. Gross margin is high, +50.2%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -8.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 8.2% higher than minimum and 81.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.5x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: ANGO
Share price, USD:  (+5.6%)5.7
year average price 7.75  


year start price 9.10 2023-03-30

max close price 11.16 2023-06-20

min close price 5.27 2024-03-25

current price 5.70 2024-03-28
Common stocks: 39 509 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  9.5%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  25.3%
Historical growth of EBITDA:  ---
EV / Sales: 0.7x
Margin (EBITDA LTM / Revenue): -1.8%
Fundamental value created in LTM:
Market Cap ($m): 225
Net Debt ($m): 20
EV (Enterprise Value): 245
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-19Business Wire

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

2024-03-15Zacks Investment Research

AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors

2024-03-08Zacks Investment Research

Why AngioDynamics (ANGO) Dipped More Than Broader Market Today

2024-02-22Zacks Investment Research

Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today

2024-02-16Zacks Investment Research

AngioDynamics (ANGO) Divests Its PICC & Midline Businesses

2024-02-15Zacks Investment Research

Why AngioDynamics (ANGO) Outpaced the Stock Market Today

2024-02-09Zacks Investment Research

AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why

2024-01-25Zacks Investment Research

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

2024-01-08Zacks Investment Research

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

2024-01-05The Motley Fool

Why AngioDynamics Stock Got Destroyed Today
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4
date 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30
symbol ANGO ANGO ANGO ANGO ANGO
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2024-01-08 2023-10-05 2023-08-03 2023-03-31 2023-01-06
acceptedDate 2024-01-08 16:47:30 2023-10-05 17:15:12 2023-08-03 17:16:14 2023-03-31 14:32:28 2023-01-06 16:55:55
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2
revenue 79M 79M 91M 81M 85M
costOfRevenue 39M 39M 45M 40M 40M
grossProfit 40M 40M 46M 41M 45M
grossProfitRatio 0.509 0.509 0.509 0.502 0.528
researchAndDevelopmentExpenses 9M 8M 8M 7M 7M
generalAndAdministrativeExpenses 9M 11M 10M 9M 11M
sellingAndMarketingExpenses 25M 27M 26M 25M 26M
sellingGeneralAndAdministrativeExpenses 35M 38M 37M 34M 37M
otherExpenses -32 000 -288 000 4M 5M 5M
operatingExpenses 47M 50M 49M 46M 48M
costAndExpenses 86M 88M 94M 86M 89M
interestIncome 534 000 119 000 0 0 0
interestExpense 534 000 119 000 901 000 736 000 684 000
depreciationAndAmortization 7M 7M 8M 8M 8M
ebitda 6M -48M 5M 3M 4M
ebitdaratio 0.081 -0.608 0.055 0.031 0.049
operatingIncome -13M 35M -3M -5M -4M
operatingIncomeRatio -0.166 0.445 -0.028 -0.066 -0.043
totalOtherIncomeExpensesNet -6M 44M -19M -4M -5M
incomeBeforeTax -13M 35M -22M -10M -9M
incomeBeforeTaxRatio -0.160 0.443 -0.240 -0.120 -0.106
incomeTaxExpense 16M -11M -398 000 -179 000 -565 000
netIncome -29M 46M -21M -9M -8M
netIncomeRatio -0.367 0.583 -0.236 -0.118 -0.099
eps -0.720 1.150 -0.540 -0.240 -0.210
epsdiluted -0.720 1.150 -0.540 -0.240 -0.210
weightedAverageShsOut 40M 40M 40M 40M 39M
weightedAverageShsOutDil 40M 40M 40M 40M 39M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4
date 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30
symbol ANGO ANGO ANGO ANGO ANGO
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2024-01-08 2023-10-05 2023-08-03 2023-03-31 2023-01-06
acceptedDate 2024-01-08 16:47:30 2023-10-05 17:15:12 2023-08-03 17:16:14 2023-03-31 14:32:28 2023-01-06 16:55:55
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 61M 58M 45M 30M 30M
shortTermInvestments 0 0 0 0 0
cashAndShortTermInvestments 61M 58M 45M 30M 30M
netReceivables 52M 50M 53M 51M 53M
inventory 64M 60M 55M 64M 63M
otherCurrentAssets 9M 8M 5M 8M 13M
totalCurrentAssets 185M 175M 164M 153M 159M
propertyPlantEquipmentNet 43M 43M 44M 46M 46M
goodwill 159M 159M 159M 200M 201M
intangibleAssets 104M 107M 111M 134M 142M
goodwillAndIntangibleAssets 263M 266M 270M 334M 343M
longTermInvestments -18M -1M -13M 0 0
taxAssets 18M 1M 13M 13M 14M
otherNonCurrentAssets 8M 9M 54M -3M -4M
totalNonCurrentAssets 314M 318M 369M 390M 399M
otherAssets 0 0 0 0 0
totalAssets 500M 494M 533M 543M 558M
accountPayables 38M 25M 40M 36M 35M
shortTermDebt 2M 5M 15M 10M 0
taxPayables 608 000 2M 480 000 328 000 815 000
deferredRevenue -2M 26M -15M 13M 14M
otherCurrentLiabilities 40M 2M 43M 11M 25M
totalCurrentLiabilities 78M 57M 84M 70M 74M
longTermDebt 0 0 50M 50M 50M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 18M 1M 13M 13M 14M
otherNonCurrentLiabilities 3M 7M 8M 12M 13M
totalNonCurrentLiabilities 20M 9M 71M 76M 77M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 3M 3M 0 0 0
totalLiabilities 98M 66M 154M 145M 150M
preferredStock 198M 170M 215M 0 0
commonStock 383 000 383 000 382 000 382 000 381 000
retainedEarnings -194M -165M -211M -189M -180M
accumulatedOtherComprehensiveIncomeLoss -5M -6M -5M -4M -288 000
othertotalStockholdersEquity 401M 428M 378M 591M 588M
totalStockholdersEquity 401M 428M 378M 398M 408M
totalEquity 401M 428M 378M 398M 408M
totalLiabilitiesAndStockholdersEquity 500M 494M 533M 543M 558M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 500M 494M 533M 543M 558M
totalInvestments -18M -1M -13M 0 0
totalDebt 4M 5M 50M 60M 50M
netDebt -57M -53M 5M 30M 20M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4
date 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30
symbol ANGO ANGO ANGO ANGO ANGO
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2024-01-08 2023-10-05 2023-08-03 2023-03-31 2023-01-06
acceptedDate 2024-01-08 16:47:30 2023-10-05 17:15:12 2023-08-03 17:16:14 2023-03-31 14:32:28 2023-01-06 16:55:55
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2
netIncome -29M 46M -21M -9M -8M
depreciationAndAmortization 7M 7M 8M 8M 8M
deferredIncomeTax 16M -11M -558 000 -227 000 -618 000
stockBasedCompensation 2M 4M 3M 2M 3M
changeInWorkingCapital 8M -22M 12M 628 000 3M
accountsReceivables -2M 3M -2M 2M 406 000
inventory -4M -5M 4M -423 000 -6M
accountsPayables 16M -17M 9M -4M 6M
otherWorkingCapital -811 000 -4M 724 000 4M 2M
otherNonCashItems 1M -49M 15M 813 000 3M
netCashProvidedByOperatingActivities 5M -26M 16M 1M 7M
investmentsInPropertyPlantAndEquipment -554 000 -791 000 -1M -666 000 -1M
acquisitionsNet 0 100M 0 0 0
purchasesOfInvestments 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0
otherInvestingActivites -1M -767 000 -472 000 -1M -1M
netCashUsedForInvestingActivites -2M 98M -2M -2M -2M
debtRepayment 0 -50M -90M -45M 0
commonStockIssued -352 000 410 000 -1M 941 000 148 000
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 0 -10M 91M 45M -45 000
netCashUsedProvidedByFinancingActivities -352 000 -60M -180M 941 000 103 000
effectOfForexChangesOnCash 189 000 13 000 83 000 89 000 187 000
netChangeInCash 3M 13M 15M 254 000 5M
cashAtEndOfPeriod 61M 58M 45M 30M 30M
cashAtBeginningOfPeriod 58M 45M 30M 30M 25M
operatingCashFlow 5M -26M 16M 1M 7M
capitalExpenditure -554 000 -791 000 -1M -666 000 -1M
freeCashFlow 5M -27M 15M 704 000 6M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2023 q4
2024-01-05 ET (fiscal 2024 q2)
2023 q3
2023-10-04 ET (fiscal 2024 q1)
2023 q2
2023-07-12 ET (fiscal 2023 q4)
2023 q1
2023-03-30 ET (fiscal 2023 q3)
2022 q4
2023-01-05 ET (fiscal 2023 q2)
2022 q3
2022-10-06 ET (fiscal 2023 q1)
2022 q2
2022-07-12 ET (fiscal 2022 q4)
2022 q1
2022-04-07 ET (fiscal 2022 q3)
2021 q4
2022-01-06 ET (fiscal 2022 q2)
2021 q3
2021-09-30 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-01-05 12:00 ET
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
2023-12-21 21:01 ET
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
2023-12-07 21:01 ET
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
2023-12-07 13:00 ET
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism
2023-10-04 11:00 ET
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
2023-09-12 20:01 ET
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
2023-08-15 20:01 ET
AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation
2023-08-03 12:00 ET
AngioDynamics Completes Enrollment for PRESERVE Clinical Study
2023-07-31 20:01 ET
AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference
2023-07-24 20:01 ET
AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
2023-07-12 11:00 ET
AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance
2023-06-20 20:01 ET
AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023
2023-06-08 20:01 ET
AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million
2023-04-11 20:01 ET
AngioDynamics to Present at the Needham Virtual Healthcare Conference
2023-03-30 11:00 ET
AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance
2023-03-13 20:01 ET
AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023
2023-02-28 13:00 ET
AngioDynamics to Participate in Three Investor Conferences in March
2023-01-05 12:00 ET
AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance
2022-12-20 21:01 ET
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
2022-12-15 21:01 ET
AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023
2022-11-17 21:01 ET
AngioDynamics to Present at the Piper Sandler Healthcare Conference
2022-10-31 20:01 ET
AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism
2022-10-06 11:00 ET
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance
2022-09-08 20:01 ET
AngioDynamics to Report Fiscal 2023 First Quarter Financial Results on October 6, 2022
2022-08-03 20:01 ET
AngioDynamics to Present at the Canaccord Genuity Growth Conference
2022-07-12 11:00 ET
AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance
2022-06-15 20:01 ET
AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022
2022-05-16 20:01 ET
AngioDynamics to Present at the UBS Global Healthcare Conference
2022-05-03 20:01 ET
AngioDynamics to Present at the BofA Securities Healthcare Conference
2022-04-07 11:00 ET
AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance
2022-04-04 20:01 ET
AngioDynamics to Present at the Needham Virtual Healthcare Conference
2022-03-14 20:01 ET
AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022
2022-03-08 21:01 ET
AngioDynamics to Present at Three Investor Conferences in March
2022-02-08 21:01 ET
AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2022-01-06 12:00 ET
AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance
2022-01-03 21:01 ET
AngioDynamics to Present at the Needham Virtual Growth Conference
2021-12-15 21:01 ET
AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022
2021-09-30 11:00 ET
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
2021-09-15 20:01 ET
AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021
2021-07-29 20:01 ET
AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference
2021-07-13 11:00 ET
AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results
2021-07-08 22:30 ET
AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021
2021-06-24 20:01 ET
AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021
2021-06-08 11:00 ET
AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System
2021-05-17 20:01 ET
AngioDynamics to Present at the UBS Virtual Global Healthcare Conference
2021-04-12 10:00 ET
AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System
2021-04-05 20:01 ET
AngioDynamics to Present at the Needham Virtual Healthcare Conference
2021-03-30 11:00 ET
AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance
2021-03-15 20:01 ET
AngioDynamics to Participate in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum
2021-03-09 21:01 ET
AngioDynamics to Participate in a Virtual Fireside Chat at the Oppenheimer Healthcare Conference
2021-03-09 13:00 ET
AngioDynamics to Report Fiscal 2021 Third Quarter Financial Results on March 30, 2021
2021-03-01 21:01 ET
AngioDynamics to Present at the Barclays Virtual Global Healthcare Conference
2021-02-01 13:00 ET
AngioDynamics Appoints Richard C. Rosenzweig Senior Vice President, General Counsel and Secretary, Promotes Juan Carlos Serna to Senior Vice President, Scientific & Clinical Affairs
2021-01-07 12:00 ET
AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results
2021-01-04 21:01 ET
AngioDynamics to Present at the J.P. Morgan Virtual Healthcare Conference
2020-12-29 21:01 ET
AngioDynamics to Present at the Needham Virtual Growth Conference
2020-12-09 21:01 ET
AngioDynamics to Report Fiscal 2021 Second Quarter Financial Results on January 7, 2021
2020-11-12 14:00 ET
AngioDynamics Announces Presentation of Positive Safety, Efficacy Results from RAPID Outcomes Database
2020-09-29 11:00 ET
AngioDynamics Reports Fiscal 2021 First Quarter Financial Results
2020-09-21 12:00 ET
AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States
2020-09-17 20:01 ET
AngioDynamics to Report Fiscal 2021 First Quarter Financial Results on September 29, 2020
2020-08-17 12:00 ET
AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System
2020-08-03 20:01 ET
AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference
2020-07-16 11:00 ET
AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results
2020-06-23 20:01 ET
AngioDynamics to Report Fiscal 2020 Fourth Quarter and Full-Year Financial Results on July 16, 2020
2020-06-08 20:01 ET
AngioDynamics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference
2020-05-07 20:01 ET
AngioDynamics to Present at the UBS Virtual Global Healthcare Conference
2020-04-07 11:00 ET
AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results
2020-03-10 20:01 ET
AngioDynamics to Report Fiscal 2020 Third Quarter Financial Results on April 7, 2020
2020-02-27 21:01 ET
AngioDynamics to Present at Two Investor Conferences in March
2020-02-06 13:00 ET
AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer
2020-01-16 16:00 ET
AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System
2020-01-07 12:00 ET
AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results
2020-01-06 13:00 ET
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
2019-12-10 21:01 ET
AngioDynamics to Report Fiscal 2020 Second Quarter Financial Results on January 7, 2020
2019-10-22 20:01 ET
AngioDynamics Announces Departure of CFO and Appointment of Interim CFO
2019-10-03 10:02 ET
AngioDynamics Reports Fiscal 2020 First Quarter Financial Results
2019-10-03 10:00 ET
AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology
2019-09-09 12:00 ET
AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement
2019-07-31 20:01 ET
AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors
2019-04-17 20:05 ET
AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million
2019-04-17 12:01 ET
AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer
2019-04-02 11:00 ET
AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

SEC forms

Show financial reports only

SEC form 10
2024-01-08 00:00 ET
AngioDynamics reported for 2023 q4
SEC form 8
2024-01-05 07:15 ET
AngioDynamics published news for 2023 q4
SEC form 8
2024-01-05 07:15 ET
AngioDynamics reported for 2023 q4
SEC form 8
2024-01-05 07:15 ET
AngioDynamics published news for 2023 q4
SEC form 10
2023-10-05 17:15 ET
AngioDynamics reported for 2023 q3
SEC form 10
2023-10-05 00:00 ET
AngioDynamics reported for 2023 q3
SEC form 8
2023-10-04 07:15 ET
AngioDynamics reported for 2023 q3
SEC form 10
2023-08-03 00:00 ET
AngioDynamics reported for 2023 q2
SEC form 6
2023-07-12 07:30 ET
AngioDynamics reported for 2023 q2
SEC form 8
2023-07-12 00:00 ET
AngioDynamics reported for 2023 q2
SEC form 6
2023-06-14 16:39 ET
AngioDynamics published news for 2023 q1
SEC form 6
2023-06-08 17:05 ET
AngioDynamics published news for 2023 q1
SEC form 6
2023-06-02 15:36 ET
AngioDynamics published news for 2023 q1
SEC form 6
2023-06-02 07:00 ET
AngioDynamics published news for 2023 q1
SEC form 10
2023-03-31 00:00 ET
AngioDynamics reported for 2023 q1
SEC form 8
2023-03-30 00:00 ET
AngioDynamics published news for 2022 q4
SEC form 10
2023-01-06 00:00 ET
AngioDynamics reported for 2022 q4
SEC form 8
2023-01-05 00:00 ET
AngioDynamics reported for 2022 q4
SEC form 8
2022-11-30 00:00 ET
AngioDynamics published news for 2022 q3
SEC form 10
2022-10-11 00:00 ET
AngioDynamics reported for 2022 q3
SEC form 8
2022-10-06 00:00 ET
AngioDynamics reported for 2022 q3
SEC form 10
2022-07-22 00:00 ET
AngioDynamics reported for 2022 q2
SEC form 8
2022-07-12 00:00 ET
AngioDynamics reported for 2022 q2
SEC form 8
2022-04-07 00:00 ET
AngioDynamics reported for 2022 q1
SEC form 10
2022-04-07 00:00 ET
AngioDynamics reported for 2022 q1
SEC form 10
2022-01-07 00:00 ET
AngioDynamics published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
AngioDynamics published news for 2021 q4
SEC form 10
2021-09-30 00:00 ET
AngioDynamics published news for 2021 q3
SEC form 8
2021-09-30 00:00 ET
AngioDynamics published news for 2021 q2
SEC form 10
2021-07-27 00:00 ET
AngioDynamics published news for 2021 q2
SEC form 8
2021-07-13 00:00 ET
AngioDynamics published news for 2021 q2